Epalrestat sustained release (METiS Pharmaceuticals)

依帕司他缓释制剂 (METiS Pharmaceuticals)

Report date: 2025/06/30 16:21:53

Base Information

Drug NameEpalrestat sustained release (METiS Pharmaceuticals)
Drug Alias NameMTS008MTS-008
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAldose reductase inhibitors
TargetsAldose reductase
Therapy Area/IndicationsDiabetic Neuropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMETiS Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesMETiS Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsDiabetic Neuropathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A